- Kruse JJCM, Strootman EG, Wondergem J. Effects of amifostine on radiation-induced cardiac damage. Acta Oncol 2003; 42: 4-9.
- Yuhas JM. Protective drugs in cancer therapy: optimal clinical testing and future directions. Int J Radiat Oncol Biol Phys 1982; 8: 513-7.
- Hensley ML, Schlichter LM, Lindley C, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 1999; 17: 3333-55.
- Denekamp J, Stewart FA, Rojas A. Is the outlook grey for WR-2721 as a clinical radioprotector. Int J Radiat Oncol Biol Phys 1983; 9: 595-8.
- Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000; 57: 113-118
- Dubray B, Dhermain F. In regard to Antonadou et al. IJROBP 2001; 51: 915. Int J Radiat Oncol Biol Phys 2002; 53: 1395-6.
- Brizel DM, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45.
- Schlichter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-903.
- Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998; 16: 3179-90.
Acta Oncologica
Volume 42, 2003 - Issue 1